Prominent Kirkland & Ellis litigator Jay Lefkowitz, the man who led the charge to lock in Jeffrey Epstein’s notorious 2008 Florida non-prosecution agreement, is retiring from the firm after more than 30 years at the powerhouse firm.
Lefkowitz, a Columbia Law School grad, Bush White House alum, and longtime senior litigation partner (who also sat on the firm’s global management committee), announced he will retire from Kirkland & Ellis later this spring.
In his statement, he said: “Although I believe everyone is entitled to representation no matter how heinous their crimes, knowing what we all know now, I would not have taken on the matter.” He added that he’ll especially miss the camaraderie of Big Law life.
A Kirkland spokesperson put it bluntly: “To say the least, we deeply regret the firm’s 2007 representation of Jeffrey Epstein.”
Landmark Cases
Lefkowitz counts two landmark U.S. Supreme Court victories on behalf of the pharmaceutical industry as part of his legacy: the 5-4 wins in PLIVA, Inc. v. Mensing (2011) and Mutual Pharmaceutical Co. v. Bartlett (2013). Both decisions delivered sweeping federal preemption shields for generic-drug makers against state-law failure-to-warn and design-defect claims — rulings that still reverberate through product-liability dockets today. He’s also an adjunct professor at Columbia Law teaching Supreme Court advocacy.
But the recent release of voluminous DOJ Epstein files, now infamously unsealed in waves through early 2026, has put a fresh, unforgiving spotlight on Lefkowitz and Kirkland’s heavy lifting to secure that sweetheart 2008 plea.
The deal let Epstein plead to two minor state counts, serve 13 months (mostly on work release), and hand out blanket immunity to potential co-conspirators.
Newly public emails and billing records further detail post-deal personal ties: Lefkowitz inviting Epstein to his son’s bar mitzvah two years after the plea and floating a request to borrow Epstein’s private helicopter for a Hamptons jaunt.
The timing of the retirement announcement, coming just weeks after those files dropped fresh scrutiny across Big Law and academia (including at his alma mater Columbia), has tongues wagging in the AmLaw 100 corridors.
No one is calling it anything but a voluntary exit after a decorated run, but the Epstein chapter is now permanently stitched into the farewell narrative. Lefkowitz’s Kirkland bio page still lists him as active, and there’s zero indication of any push from the partnership.
In short it has been a career that reshaped pharma litigation ends under the long shadow of the client whose name still makes the industry flinch.
